Transport, metabolism, cytotoxicity and effects of novel taxanes on the cell cycle in MDA-MB-435 and NCI/ADR-RES cells

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 385, Issue 10, 2012, Pages 1035-1048

  Ehrlichová, Marie ^a   Ojima, Iwao ^b   Chen, Jin ^a   Václavíková, Radka ^a   Němcová Fürstová, Vlasta ^c   Vobořilová, Jana ^c   Šimek, Petr ^d   Horský, Stanislav ^a   Souček, Pavel ^a   Kovář, Jan ^c   Brabec, Marek ^a   Gut, Ivan ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^b STONY BROOK UNIVERSITY   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

^d INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

ABC transporters; Cell cycle; Drug metabolism; Multidrug resistance; Taxanes; Transport

Indexed keywords

ORTATAXEL; PACLITAXEL; SB T 1102; SB T 1103; SB T 1214; SB T 1216; SB T 12851; SB T 12852; SB T 12853; SB T 12854; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL STRAIN; CYTOTOXICITY; DRUG EFFECT; DRUG METABOLISM; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TRANSPORT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MDA MB 435 CELLS; NCI ADR RES CELLS;

ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR STRUCTURE; TAXOIDS;

EID: 84866729228     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-012-0785-4     Document Type: Article

References (23)

1. Aoudjit F, Vuori K (2001) Integrin signalling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20:4995-5004
2. Beer M, Lenaz L, Amador D (2008) Phase II study of ortataxel in taxane-resistant breast cancer. J Clin Oncol 26(20 supplement): 1066, abstract
3. Chien AJ, Moasser MM (2008) Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol 35(2 Suppl 2):S1-S14, quiz S39
4. Choy H (2001) Taxanes in combined modality therapy for solid tumors. Review. Crit Rev Oncol Hematol 37:237-247
5. Ehrlichová M, Václavíková R, Ojima I et al (2005) Transport and cytotoxicity of paclitaxel, docetaxel and three novel taxanes in human breast cancer cells. N-S Arch Pharmacol 372:95-105
6. Ferlini C, Distefano M, Pignatelli F, Lin S, Riva A, Bombardelli E, Mancuso S, Ojima I, Scambia G (2000) Antitumour activity of novel taxanes act at the same time as cytotoxic agents and Pglycoprotein inhibitors. Br J Cancer 83:1762-1768
7. Freedman H, Huzil JT, Luchko T, Luduena RF, Tuzsynski JA (2009) Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity. J Chem Inf Model 49:424-436
8. Galletti E, Magnani M, Renzulli ML, Botta M (2007) Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. Chem Med Chem 7:920-942
9. Garg MB, Ackland SP (2000) Simple and sensitive high-performance liquid chromatography. Method for determination of docetaxel in human plasma and urine. J Chromatog B 748:383-388
10. Gut I, Danielova V, Holubova J, Soucek P, Kluckova H (2000) Cytotoxicity of cyclophosphamide, paclitaxel, and docetaxel for tumor cell lines in vitro: effects of concentration, time and cytochrome P450-catalyzed metabolism. Arch Toxicol 74:437-446
11. Gut I, Václavíková R, Simek P, Ojima I,Horsky S, Soucek P, Kondrova E (2006) Metabolism of new generation taxanes in human, pig, minipig and rat liver microsomes. Xenobiotica 36:772-792
12. Hastie TJ, Tibshirani RJ (1990) Generalized additive models. Chapman and Hall/CRC, London
13. Kovář J, Ehrlichová M, Šmejkalová B, Zanardi I, Ojima I, Gut I (2009) Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells. Anticancer Res 29:2951-2960
14. Miller ML, Ojima I (2001) Chemistry and chemical biology of taxane anticancer agents. Chem Rec 1:195-211
15. Monks A, Harris E, Hose C, Connelly J, Sausville EA (2003) Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3- methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 63:766-772
16. Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P, Bernacki RJ (1996) Synthesis and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J Med Chem 39:3889-3896
17. Rowinsky EK (1997) The development and clinical utility of taxane class of antimicrotubule chemotherapy agents. Annu RevMed 48:353-374
18. Sackett D, Fojo T (1997) Taxanes. Review. Canc Chemother Biol Response Modif 17:59-79
19. Schiff PB, Horwitz SB (1981) Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 20:3247-3252
20. Václaviková R,Horsky S, Simek P, Gut I (2003) The paclitaxelmetabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn-Schmiedebergs Arch Pharmacol 368:200-209
21. Václaviková R, Nordgard SH, Alnaes GIG, Hubackova M, Kubala E, Kodet R, Mrhalova M, Novotny J, Gut I, Kristensen VN, Soucek P (2008) Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1); effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenetics Genom 18:263-273
22. Vobořilová J, Němcová-Fürstová V, Neubauerová J, Ojima I, Zanardi I, Gut I, Kovář J (2011) Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells. Invest New Drugs 29(3):411-423
23. Wood SN (2006) Generalized additive models: an introduction with R. Chapman and Hall/CRC, London, 391 pages